Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials

Open access

Abstract

Background: Pirfenidone is an oral antifibrotic agent that has been shown to reduce the decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). We performed an integrated analysis of safety data from five clinical trials evaluating pirfenidone in patients with IPF. Methods: All patients treated with pirfenidone in the three multinational Phase 3 studies (CAPACITY (studies 004 and 006), ASCEND (study 016)) and two ongoing open-label studies (study 002 and study 012 (RECAP)) were included in the analysis. Safety outcomes were assessed during the period from the first dose until 28 days after the last dose of study drug. Results: A total of 1299 patients were included in the analysis. The cumulative total exposure to pirfenidone was 3160 person exposure years (PEY). The median duration of exposure was 1.7 years (range 1 week to 9.9 years), and the mean (±SD) daily dose was 2053.8 (±484.9) mg. Gastrointestinal events (nausea (37.6%), diarrhoea (28.1%), dyspepsia (18.4%), vomiting (15.9%)) and rash (25.0%) were the most common adverse events; these were generally mild to moderate in severity and without significant clinical consequence. Elevations in alanine aminotransferase or aspartate aminotransferase greater than three times the upper limit of normal occurred in 40/1299 (3.1%) patients (adjusted incidence, 2.3 per 100 PEY). Elevations were generally transient and reversible with dose modification or discontinuation. Conclusions: A comprehensive analysis of safety outcomes in a large and well-defined cohort of 1299 patients with IPF who were followed prospectively for up to 9.9 years demonstrated that long-term treatment with pirfenidone is safe and generally well tolerated. Trial registration numbers: NCT00287716, NCT00287729, NCT00662038, NCT01366209.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjresp-2015-000105

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study profile.
Figure 1 Study profile.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 143

Metadata

Authors
Lancaster, L., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., King, T. E., Lederer, D. J., Lin, Z., Nathan, S. D., Pereira, C. A., Swigris, J. J., Valeyre, D., & Noble, P. W.
Affiliations
  • Vanderbilt University Medical Center (US)
  • University of Turin (IT)
  • InterMune Inc, Brisbane, California, USA
  • Ruhrlandklinik (DE)
  • Emeritus Professor of Respiratory Medicine, Imperial College, London, UK
  • The Alfred Hospital (AU)
  • University of Miami (US)
  • University of California, San Francisco (US)
  • Columbia University Irving Medical Center (US)
  • Inova Fairfax Hospital (US)
  • Universidade Federal de São Paulo (BR)
  • National Jewish Health (US)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Cedars-Sinai Medical Center (US)
Corresponding author
Lancaster, Lisa
Venue
BMJ Open Respiratory Research
Publisher
BMJ
Published
2016-01
Volume
3
Issue
1
Pages
e000105
ISSN
2052-4439 (ISSN-L)
OpenAlex
W2235270260
Cited by
132
References
11
Citations by year
2026: 6 · 2025: 2 · 2024: 11 · 2023: 8 · 2022: 7 · 2021: 6 · 2020: 23 · 2019: 12 · 2018: 20 · 2017: 28 · 2016: 8
FWCI
20.26
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ Open Respiratory Research (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Monash University Research Portal (Monash University) (submittedVersion, cc-by-nc)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Funders
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Russian Science Foundation
  • Genentech
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
pirfenidone, idiopathic pulmonary fibrosis, drug safety, long-term tolerability, antifibrotic therapy, gastrointestinal adverse effects, rash, elevated liver enzymes, cumulative drug exposure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. https://app.cochat.ai/papers/10.1136/bmjresp-2015-000105
The paper
Lancaster, L., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., King, T. E., Lederer, D. J., Lin, Z., Nathan, S. D., Pereira, C. A., Swigris, J. J., Valeyre, D., & Noble, P. W. (2016). Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respiratory Research. https://doi.org/10.1136/bmjresp-2015-000105

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.